An article previewing a clinical trial report on an oral GLP-1 small-molecule pill for weight loss, explaining the study type and reader value.
Key Takeaways
- Aleniglipron produced up to 12.1% mean bodyweight reduction over 36 weeks in treated participants
- Drug is an oral once-daily small molecule that can be taken with or without food
- Trial was randomized, double-blind, and placebo-controlled and reported in Nature Medicine